Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IGUANA-1 is a potent and highly selective small molecule inhibitor of aldehyde dehydrogenase 1B1 (ALDH1B1), an enzyme implicated in the growth and maintenance of colorectal cancer cells and organoids. IGUANA-1 demonstrates strong antitumor activity in preclinical models with minimal mitochondrial toxicity, distinguishing it from related compounds. Molecular studies confirm that IGUANA-1 binds the active site of ALDH1B1 and inhibits its function at nanomolar concentrations. IGUANA-1 is used as a tool compound in cancer research and has not been reported to be in clinical trials or approved for human therapeutic use[1][3][5][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on IGUANA-1.